MX2007009985A - Diastereoisomers of 4-hydroxyisoleucine and uses thereof. - Google Patents
Diastereoisomers of 4-hydroxyisoleucine and uses thereof.Info
- Publication number
- MX2007009985A MX2007009985A MX2007009985A MX2007009985A MX2007009985A MX 2007009985 A MX2007009985 A MX 2007009985A MX 2007009985 A MX2007009985 A MX 2007009985A MX 2007009985 A MX2007009985 A MX 2007009985A MX 2007009985 A MX2007009985 A MX 2007009985A
- Authority
- MX
- Mexico
- Prior art keywords
- hydroxyisoleucine
- diabetes
- type
- isomers
- diastereoisomers
- Prior art date
Links
- OSCCDBFHNMXNME-WDCZJNDASA-N (2s,3s,4r)-2-amino-4-hydroxy-3-methylpentanoic acid Chemical compound C[C@@H](O)[C@@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-WDCZJNDASA-N 0.000 title abstract 2
- OSCCDBFHNMXNME-UHFFFAOYSA-N gamma-hydroxyisoleucine Natural products CC(O)C(C)C(N)C(O)=O OSCCDBFHNMXNME-UHFFFAOYSA-N 0.000 title abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000023852 carbohydrate metabolic process Effects 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002473 insulinotropic effect Effects 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to configurational isomers 4-hydroxyisoleucine, and to lactones, pharmaceutically acceptable salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. The isomers of the invention exhibit insulinotropic activity and thus may be useful for the prevention and treatment of disorders of carbohydrate or lipid metabolism, including diabetes mellitus (type 1 and type 2 diabetes), pre-diabetes, and Metabolic Syndrome.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65441305P | 2005-02-18 | 2005-02-18 | |
| PCT/IB2006/001758 WO2006117696A2 (en) | 2005-02-18 | 2006-02-17 | Diastereoisomers of 4-hydroxyisoleucine and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007009985A true MX2007009985A (en) | 2008-03-11 |
Family
ID=37086084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007009985A MX2007009985A (en) | 2005-02-18 | 2006-02-17 | Diastereoisomers of 4-hydroxyisoleucine and uses thereof. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1853552A2 (en) |
| JP (1) | JP2008530198A (en) |
| CN (1) | CN101128418A (en) |
| AU (1) | AU2006242851A1 (en) |
| BR (1) | BRPI0607140A2 (en) |
| CA (1) | CA2598491A1 (en) |
| MX (1) | MX2007009985A (en) |
| WO (1) | WO2006117696A2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006256442A1 (en) * | 2005-03-22 | 2006-12-14 | Bellus Health (Innodia) Inc. | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
| WO2008154743A1 (en) * | 2007-06-19 | 2008-12-24 | Innodia Inc. | Methods for the synthesis of 4-hydroxyisoleucine, stereoisomers and analogs thereof |
| WO2009085180A1 (en) * | 2007-12-20 | 2009-07-09 | The Feinstein Institute For Medical Research | Treatment of sepsis and inhibition of mif by d-t4 |
| CN121102186A (en) * | 2015-10-23 | 2025-12-12 | 纳维托制药有限公司 | SESTRIN-GATOR2 interaction modulators and uses thereof |
| AU2018258355B2 (en) | 2017-04-26 | 2024-05-30 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
| US11345654B2 (en) | 2018-10-24 | 2022-05-31 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| CN114786660A (en) | 2019-11-01 | 2022-07-22 | 纳维托制药有限公司 | Methods of treatment using modulators of MTORC1 |
| CN112089710B (en) * | 2020-08-07 | 2022-04-01 | 郑州大学 | Application of 4-hydroxyisoleucine in preparation of antitumor drugs |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2797767B1 (en) * | 1999-08-27 | 2002-06-14 | Centre Nat Rech Scient | USE OF AMINO ACIDS FOR THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF INSULIN RESISTANCES |
| EP1701735A4 (en) * | 2003-10-27 | 2009-12-09 | Innodia Inc | Use of hydroxylated amino acids for treating diabetes |
| EP1657236A1 (en) * | 2004-11-10 | 2006-05-17 | Centre National De La Recherche Scientifique (Cnrs) | Method for preparing diastereoisomers of 4-hydroxy isoleucine |
-
2006
- 2006-02-17 CA CA002598491A patent/CA2598491A1/en not_active Abandoned
- 2006-02-17 BR BRPI0607140-6A patent/BRPI0607140A2/en not_active Application Discontinuation
- 2006-02-17 CN CNA2006800050682A patent/CN101128418A/en active Pending
- 2006-02-17 EP EP06765601A patent/EP1853552A2/en not_active Withdrawn
- 2006-02-17 AU AU2006242851A patent/AU2006242851A1/en not_active Abandoned
- 2006-02-17 MX MX2007009985A patent/MX2007009985A/en not_active Application Discontinuation
- 2006-02-17 WO PCT/IB2006/001758 patent/WO2006117696A2/en not_active Ceased
- 2006-02-17 JP JP2007555732A patent/JP2008530198A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1853552A2 (en) | 2007-11-14 |
| WO2006117696A2 (en) | 2006-11-09 |
| CA2598491A1 (en) | 2006-11-09 |
| WO2006117696A3 (en) | 2007-01-25 |
| CN101128418A (en) | 2008-02-20 |
| JP2008530198A (en) | 2008-08-07 |
| AU2006242851A1 (en) | 2006-11-09 |
| BRPI0607140A2 (en) | 2009-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007061661A3 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| WO2009091576A3 (en) | Parenteral formulations of dopamine agonists | |
| MX2009003305A (en) | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2. | |
| UA102429C2 (en) | Pharmaceutical composition comprising an sglt2 inhibitor, a dppiv inhibitor and a third antidiabetic agent and use thereof | |
| WO2006002909A3 (en) | Sphingolipids against pathological processes in lipid rafts | |
| WO2011005811A8 (en) | Combination therapy for the treatment of diabetes | |
| WO2008134828A3 (en) | Tissue degeneration protection | |
| UA100384C2 (en) | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative | |
| WO2008055940A8 (en) | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions | |
| CA2478237A1 (en) | Use of adapalene for the treatment of dermatological disorders | |
| EP2982696A3 (en) | Treatment of acute lymphoblastic leukemia | |
| WO2007067495A3 (en) | Levodopa prodrug mesylate, compositions thereof, and uses thereof | |
| WO2007064931A3 (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| WO2007059372A3 (en) | Use of chloroquine to treat metabolic syndrome | |
| WO2008124505A3 (en) | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders | |
| WO2006099941A8 (en) | Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments | |
| EA200900940A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING PYRAZOL-O-GLUCOSIDE DERIVATIVE | |
| MY148844A (en) | Fumarate salt of (alpha s, beta r)-6- bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol | |
| WO2006120574A3 (en) | Analogs of 4-hydroxyisoleucine and uses thereof | |
| IL181095A (en) | Polysulfated glycosides and salts thereof and pharmaceutical compositions comprising them | |
| PL2205279T3 (en) | Pharmaceutical combination of aliskiren and valsartan | |
| MX2007009985A (en) | Diastereoisomers of 4-hydroxyisoleucine and uses thereof. | |
| WO2007016679A3 (en) | Combination immediate release controlled release levodopa and carbidopa dosage forms | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| WO2006131836A3 (en) | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |